Acetylcholine News and Research RSS Feed - Acetylcholine News and Research

Researchers devise lipid-based diets to relieve symptoms of Alzheimer's disease

Researchers devise lipid-based diets to relieve symptoms of Alzheimer's disease

Alzheimer´s disease (AD) is the most common disease underlying memory problems and dementia in the elderly. One of the invariable pathologies in AD is degeneration of cholinergic synapses in brain cortex and hippocampus. [More]
Vestibular test may aid ocular myasthenia gravis diagnosis

Vestibular test may aid ocular myasthenia gravis diagnosis

Assessing extraocular muscle activity by recording ocular vestibular evoked myogenic potentials is a promising test for isolated ocular myasthenia gravis, report researchers. [More]
Anticholinergic medications may not be best option for dementia patients in rehab facility

Anticholinergic medications may not be best option for dementia patients in rehab facility

During rehabilitation following an acute hospital stay, medications that block neurotransmitters may be overprescribed to older patients suffering from delirium superimposed on dementia, according to health researchers. [More]
Anticholinesterase offers a ‘steadying hand’ to PD patients

Anticholinesterase offers a ‘steadying hand’ to PD patients

The dementia drug rivastigmine may reduce the risk of falls in patients with Parkinson’s disease by improving gait stability, findings from the phase II ReSponD trial show. [More]
Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Oral drug rivastigmine could help prevent falls in people with Parkinson’s

Scientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson’s. [More]
Small differences in specific genetic variant could alter nicotine consumption

Small differences in specific genetic variant could alter nicotine consumption

Nicotine is an addictive substance and genetic factors are known to play a role in smoking behaviors. Recently, a team of researchers at Penn State and the University of Colorado determined how small differences in a particular region of the mouse genome can alter nicotine consumption. [More]
Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors. [More]
Novel method for examining small molecules may provide platform for new drug design

Novel method for examining small molecules may provide platform for new drug design

Most pharmaceutical drugs consist of tiny molecules, which target a class of proteins found on the surfaces of cell membranes. Studying these subtle interactions is essential for the design of effective drugs, but the task is extremely challenging. [More]
Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain. [More]
First patients screened in Axovant's phase 3 study of RVT-101

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program. [More]
Cannabinoid receptors of the brain control aversive memories that are crucial for survival

Cannabinoid receptors of the brain control aversive memories that are crucial for survival

Memory is not a simple box of souvenirs; it is also, and most importantly, a safety system for organisms. With the help of negative memories, known as "aversive" memories, we can avoid a threat that we have already confronted. Researchers from Inserm and University of Bordeaux have just discovered that the cannabinoid receptors of the brain control these memories that are crucial for survival. [More]
Common Alzheimer's disease drug increases bone density, reduces fracture risks

Common Alzheimer's disease drug increases bone density, reduces fracture risks

The most common drug used to treat Alzheimer's disease increases bone mass in mice, according to one of the first research articles published in the new open access journal Heliyon. The authors of the study, from Saitama Medical University in Japan, say this means the drug could also be used to treat bone loss diseases like osteoporosis and periodontitis, following further clinical research. [More]
Researchers identify protein that regulates neuron growth

Researchers identify protein that regulates neuron growth

An international team of researchers, led by scientists at the National University of Singapore (NUS), has identified a protein that regulates the growth of neurons by transporting key metabolic enzymes to the tips of neural cells. [More]
Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression. [More]
Adequate intake of choline essential for good health and physical performance

Adequate intake of choline essential for good health and physical performance

Athletes and physically active people of all ages can benefit from choline not only for their overall health, but also because it supports muscle performance during exercise, and can improve stamina. [More]
Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA). [More]
Cholinergic neurons in basal forebrain broadcast message throughout the cerebral cortex

Cholinergic neurons in basal forebrain broadcast message throughout the cerebral cortex

When a large combat unit, widely dispersed in dense jungle, goes to battle, no single soldier knows precisely how his actions are affecting the unit's success or failure. But in modern armies, every soldier is connected via an audio link that can instantly receive broadcasts - reporting both positive and negative surprises - based on new intelligence. The real-time broadcasts enable dispersed troops to learn from these reports and can be critical since no solider has an overview of the entire unit's situation. [More]
Brain cells in Parkinson's disease die prematurely, burning out like an overheating motor

Brain cells in Parkinson's disease die prematurely, burning out like an overheating motor

The death of brain cells in Parkinson's disease may be caused by a form of cellular energy crisis in neurons that require unusually high quantities of energy to carry out their job of regulating movement, researchers at the University of Montreal reported today. [More]
Possible link discovered between common medications and falls in older men

Possible link discovered between common medications and falls in older men

Serious falls are more than twice as likely in older men who take medicines with anti-cholinergic properties - according to new research from the University of East Anglia. [More]
Intestinal bacteria play crucial role in inducing anxiety, depression

Intestinal bacteria play crucial role in inducing anxiety, depression

Scientists from the Farncombe Family Digestive Health Research Institute at McMaster University have discovered that intestinal bacteria play an important role in inducing anxiety and depression. [More]
Advertisement
Advertisement